Description
Hydroxypropyl-beta-cyclodextrin, also known as Hydroxypropyl-beta-cyclodextrin; THPB; HP-beta-CD; HPbCD; HP-beta-CyD; VTS-270; HPbetaCD; HPbetaCyD, is a drug candidate potentially for the treatment of Niemann-Pick type C diseases. In April 2009, hydroxypropyl-beta-cyclodextrin (HPbCD) was first approved